Penn Medicine is now home to one of the first fully accredited Pulmonary Hypertension Care Centers (PHCCs) in the country, with its Pulmonary Hypertension/Pulmonary Vascular Disease Program at Penn Presbyterian Medical Center and the Hospital of the University of Pennsylvania. The Pulmonary Hypertension Association (PHA) just announced its first six accredited programs as part of their efforts to improve overall quality of care and ultimately improve outcomes of patients with pulmonary hypertension (PH), specifically pulmonary arterial hypertension (PAH) — a rare and debilitating disease of the lungs that affects the functioning of the heart and can lead to right heart failure.
PHCC accreditation signifies that a PH program is dedicated to making a proper diagnosis and has the capacity to appropriately and comprehensively manage PH patients according to a set of criteria established by the PHA Scientific Leadership Council — 28 global leaders in the field of pulmonary hypertension. These criteria have also been developed with input from many PH stakeholders including physicians, allied health care professionals, patients and PHA leadership and are considered essential to delivering high-quality care for these complex patients.
For more information on the announcement, please visit: